Compare NEUP & IRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NEUP | IRIX |
|---|---|---|
| Founded | 1996 | 1989 |
| Country | United States | United States |
| Employees | 8 | N/A |
| Industry | | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.0M | 25.8M |
| IPO Year | N/A | 1996 |
| Metric | NEUP | IRIX |
|---|---|---|
| Price | $4.41 | $1.45 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $21.00 | N/A |
| AVG Volume (30 Days) | 26.4K | ★ 54.4K |
| Earning Date | 01-01-0001 | 04-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 8.47 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,593,000.00 |
| Revenue This Year | N/A | $9.61 |
| Revenue Next Year | N/A | $8.12 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.65 | $0.78 |
| 52 Week High | $21.31 | $1.65 |
| Indicator | NEUP | IRIX |
|---|---|---|
| Relative Strength Index (RSI) | 59.15 | 54.39 |
| Support Level | $3.99 | $1.33 |
| Resistance Level | $4.56 | $1.51 |
| Average True Range (ATR) | 0.18 | 0.07 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 83.93 | 62.50 |
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.
IRIDEX Corp is involved in the business of developing, manufacturing, and marketing laser-based medical systems, delivery devices, and consumable instrumentation for ophthalmology. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.